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Abstract
Purpose: Response assessment to definitive non-surgical treatment for head and
neck squamous cell carcinoma (HNSCC) is centered on the role of 18F-
fluorodeoxyglucose (FDG) positron emission tomography/computed tomography
(PET-CT) 12 weeks after treatment. The 5-point Hopkins score is the only qualitative
system available for standardized reporting, albeit limited by suboptimal positive
predictive value (PPV). The aim of our study was to explore the feasibility and assess
the diagnostic accuracy of an experimental 6-point scale (“Cuneo score”).
Methods: We performed a retrospective, multicenter study on HNSCC patients who
received a curatively-intended, radiation-based treatment. A centralized, independent
qualitative evaluation of post-treatment FDG-PET/CT scans was undertaken by 3
experienced nuclear medicine physicians who were blinded to patients’ information,
clinical data, and all other imaging examinations. Response to treatment was
evaluated according to Hopkins, Cuneo, and Deauville criteria. The primary endpoint
of the study was to evaluate the PPV of Cuneo score in assessing locoregional
control (LRC). We also correlated semi-quantitative metabolic factors as included in
PERCIST and EORTC criteria with disease outcome.
(Continued on next page)
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Results: Out of a total sample of 350 patients from 11 centers, 119 subjects
(oropharynx, 57.1%; HPV negative, 73.1%) had baseline and post-treatment FDG-PET/
CT scans fully compliant with EANM 1.0 guidelines and were therefore included in
our analysis. At a median follow-up of 42 months (range 5-98), the median
locoregional control was 35 months (95% CI, 32-43), with a 74.5% 3-year rate. Cuneo
score had the highest diagnostic accuracy (76.5%), with a positive predictive value for
primary tumor (Tref), nodal disease (Nref), and composite TNref of 42.9%, 100%, and
50%, respectively. A Cuneo score of 5-6 (indicative of residual disease) was associated
with poor overall survival at multivariate analysis (HR 6.0; 95% CI, 1.88-19.18; p =
0.002). In addition, nodal progressive disease according to PERCIST criteria was
associated with worse LRC (OR for LR failure, 5.65; 95% CI, 1.26-25.46; p = 0.024) and
overall survival (OR for death, 4.81; 1.07-21.53; p = 0.04).
Conclusions: In the frame of a strictly blinded methodology for response
assessment, the feasibility of Cuneo score was preliminarily validated. Prospective
investigations are warranted to further evaluate its reproducibility and diagnostic
accuracy.
Keywords: Head and neck cancer, Radiotherapy, 18F-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography, Diagnostic accuracy, Positive
predictive value
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-
skin cancer worldwide (Rettig & D’Souza, 2015). In over 60% of cases, a non-
metastatic locally advanced disease is found at diagnosis. Since about 20 years (Pignon
et al., 2000; Pignon et al., 2009), concurrent chemo-radiotherapy (CRT) is the non-
surgical mainstay of treatment for unresectable disease and organ preservation pur-
pose. Historically, a 5-year survival rate of about 50% has been reported (Carvalho
et al., 2005; Bathia & Burtness, 2015). Response evaluation to CRT is of critical im-
portance for HNSCC management. In this respect, it is commonly recognized that
morphologic imaging modalities may be suboptimal (Bhatnagar et al., 2013), particu-
larly due to fibrosis, edema, and inflammatory changes mainly induced by radiation
(RT). In analogy to non-small cell lung cancer (Iravani et al., 2019) and Hodgkin
lymphoma (HL) (Cheson et al., 2014), metabolic information provides undisputed
benefit to aid treatment response assessment in HNSCC. In particular, level one evi-
dence (Mehanna et al., 2016) supports the notion that surveillance based on a nega-
tive 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed
tomography (FDG-PET/CT) acquired at a minimum of 12 weeks after CRT is non-
inferior to an invasive strategy based on planned neck dissection in terms of long-
term survival. The importance to apply standardized measures for FDG-PET/CT
assessment has been highlighted by the widespread clinical use of Deauville criteria in
HL management (Barrington & Kluge, 2017), whereby the metabolic pattern of in-
terim response to chemotherapy (CHT) was demonstrated (Barrington et al., 2019) to
be correlated with long-term outcome. In the setting of HNSCC, consistent qualita-
tive evaluations in the post-treatment scenario are scarce. In this regard, the only rec-
ognized scoring system is represented by the “Hopkins criteria,” firstly introduced by
Marcus et al. (Marcus et al., 2014). In a retrospective single-center study on 214
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HNSCC patients treated at Johns Hopkins University in a time span of 13 years
(2000-2013), the authors were able to show that a prespecified 5-point scale allowed
to discriminate a complete versus an incomplete response to RT or CRT with a nega-
tive predictive value (NPV) and overall diagnostic accuracy of 91.1% and 86.9%, re-
spectively. In a prospective, multicenter study (Van Den Wyngaert et al., 2017)
focused on the standardized implementation and reporting of FDG-PET/CT acquired
at 12 weeks after CRT, the use of Hopkins criteria yielded a NPV of 92.1%. Overall,
the excellent diagnostic performance associated with a negative FDG-PET/CT scan is
however counterbalanced by its suboptimal positive predictive value (PPV), an unre-
solved issue in head and neck oncology. To compensate for this known limitation, in-
tegrating metabolic information with clinical data and morphologic imaging is
essential for proper response assessment and surveillance. In a meta-analysis (Gupta
et al., 2011) on 2335 patients from 51 studies, a mean pooled PPV of 58.6% was ob-
tained. A more recent meta-analysis (Helsen et al., 2018) from 20 studies (1293 sub-
jects) yielded the same PPV (58%). In both Johns Hopkins retrospective experience
(Marcus et al., 2014) and ECLYPS study (Van Den Wyngaert et al., 2017), a PPV of
71.1% and 62.5% was reported, respectively. In this perspective, the discriminative
power of Hopkins score may be inherently limited. We hypothesized that the poten-
tial limitation of a 5-point scoring system such as the Hopkins criteria may be over-
come by a more sensitive 6-point scale discriminating patients with complete,
incomplete or equivocal response to treatment, identifying a threshold score of re-
sponse for each of the 3 patterns. Ideally, it would be noteworthy to apply standard-
ized diagnostic criteria able to minimize false negative but also false-positive results: a
high PPV may allow to better address the common development of inflammatory re-
actions after RT and the slow nodal disease regression of HPV positive disease
(Huang et al., 2013), factors known to impair the FDG-PET/CT evaluation 12 weeks
after treatment in both the PET-NECK (Mehanna et al., 2016) and ECLYPS (Van Den
Wyngaert et al., 2017) trials. The aim of our study was to test the reproducibility and
evaluate the diagnostic accuracy of an experimental 6-point scale in assessing the re-
sponse to curatively—intended treatment for HNSCC. In addition, we sought to in-
vestigate whether baseline semi-quantitative metabolic factors or their change after
treatment (“delta”) as included in PERCIST (JH et al., 2016) and EORTC (Young
et al., 1999) criteria correlated with disease outcome.
Methods
Design and setting of the study
We performed an observational, retrospective, multi-center study within the Italian
Association of Radiotherapy and Clinical Oncology (AIRO). In order to overcome
the potential limitations of retrospective assessments in the field of functional im-
aging, a rigorous centralized review of FDG-PET/CT scans was mandated per
protocol and performed by 3 independent nuclear medicine physicians (AB, SM,
VB). The study was approved by the local ethics committees of each participating
center. Participating Nuclear Medicine centers needed to have clinical trial qualifi-
cation released from the “Federazione Italiana Linfomi” (FIL) core lab (Chauvie
et al., 2016).
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Patients’ characteristics
Consecutive patients treated between 1/1/10 and 31/12/15 could be enrolled in our
study. Performance status (PS) according to Eastern Cooperative Oncology Group
(ECOG), smoking history and comorbidity profile according to Charlson comorbid-
ity index (CCI) (Charlson et al., 1987) were recorded at HNSCC diagnosis. Patients
with non-metastatic, histologically proven squamous cell carcinoma of the orophar-
ynx, hypopharynx, larynx and nasopharynx, or undifferentiated nasopharyngeal car-
cinoma candidate to non-surgical treatment with curative intent could be included.
Pending inclusion in the study, a baseline and post-treatment FDG-PET/CT exami-
nations had to be available for each subject. By definition, the baseline scan had to
be executed not before 8 weeks from the start of treatment (first day of RT or first
cycle of induction CHT, if performed). The post-treatment scan had to be executed
not before 10 weeks and no later than 6 months after the end of treatment (last
RT fraction). Clinical stage was defined based on TNM/AJCC 7th edition. Human
papilloma virus (HPV) status was not routinely available in all centers in the con-
sidered timeframe. HPV positivity was defined by a 70% diffuse nuclear staining
detected by p16 immunohistochemistry, with additional HPV-DNA in situ hybrida-
zation as confirmatory test in selected cases. A curatively intended treatment was
defined as one of the following: RT alone; cisplatin-based concurrent CRT;
cetuximab-based concurrent CRT; induction CHT followed by RT alone; induction
CHT followed by concurrent CRT. Prior RT to the head and neck region and
gross total excision of both primary and/or nodal disease before index treatment
were not allowed. No upper age limit was defined.
FDG-PET/CT analysis
Only FDG-PET/CT scans performed according to EANM 1.0 procedure guidelines
(Boellard et al., 2010) were evaluated. No contrast media for the CT component of
FDG PET/CT examinations were used. Moreover, a strict criterion for uptake time was
applied. In fact, only patients whose both baseline and post-treatment scans were ac-
quired within the range of 60 + 10 min after FDG injection were ultimately included in
our study (supplementary material).
An independent evaluation of all FDG-PET/CT images was undertaken by 3 experi-
enced nuclear medicine physicians who were blinded to patients’ information, clinical
data, and other imaging examinations. Anthropometric variables (weight, height, and
sex) and selected technical parameters (administered activity of FDG per kilogram,
plasma glucose level at time of scan, uptake time) were automatically provided for each
case. A qualitative assessment of all post-treatment scans was performed in accordance
with 2 standardized reporting systems, Hopkins and Deauville criteria. In addition, an
experimental 6-point score (“Cuneo score” was tested (Table 1)). Deauville criteria were
experimentally applied to HNSCC. The 3 scores were determined by each reviewer for
the primary tumor (Tref) and nodal disease (Nref), respectively. A composite TNref
score was also calculated, corresponding to the highest score reported. By definition,
the diagnostic accuracy of the 3 qualitative scores was assessed on all those cases where
an agreement of at least 2 of the 3 reviewers was found. To this end, a secondary revi-
sion of selected cases without initial agreement of at least 2 reviewers was allowed prior
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to the final analysis to rule out major discrepancies. Response according to PERCIST
and EORTC criteria was also computed (supplementary material).
Statistical analysis
Inter-observer agreement was measured with the Krippendorff’s alpha coefficient at 3-
time points: after a blinded review of a “training set” of 15 patients (phase 1), after a
second review of the “training set” (phase 2), and after the revision of the whole cohort
enrolled (phase 3). After feedback from phase 1, a meeting was held to discuss inter-
pretation, and a detailed set of instructions for the review procedure was agreed and
acted upon.
Response to treatment was assessed by local investigators in accordance with the
RECIST 1.1 criteria (Therasse et al., 2000). Progression-free survival (PFS) was defined
as the time from the last day of treatment to the date of the first of the following
events: the first day when criteria for progressive disease (PD) are met; salvage surgery
or elective neck dissection after 15 weeks from the last day of RT performed on the
clinical or radiological evidence of progression; death for any cause. The type of first
PFS event was selected among the following: local failure (i.e, primary tumor); regional
failure (i.e, lymph nodes); simultaneous local and nodal failure; distant failure; second
primary tumor. Loco-regional control (LRC) was defined as the time from the last day
of treatment to the date of the first loco-regional event. Overall survival (OS) was de-
fined as the time from the date of HNSCC diagnosis to death from any cause or last
follow-up. LRC, PFS, and OS were estimated by the Kaplan-Meyer method. In order to
evaluate whether specific patient, disease, and treatment features or FDG-PET/CT re-
sponse pattern had a potential prognostic impact on outcome, Cox regression analysis
was performed, by calculation of hazard ratios (HR) and corresponding 95% confidence
intervals (CI 95%). A multivariate analysis was performed when multiple risk factors
Table 1 Standardized reporting criteria used to assess FDG-PET/CT scans (Deauville, Hopkins, and
Cuneo scores)
Light blue, red, and light gray boxes corresponding to scores indicative of absence of disease, presence of disease or
equivocal finding, respectively
Bonomo et al. European Journal of Hybrid Imaging             (2020) 4:8 Page 5 of 16
with a p value < 0.05 were identified in the univariate analysis. Median LRC, PFS, and
OS and their estimates at 36 months were calculated with corresponding 95% CI. For
each standardized qualitative score (Deauville, Hopkins, and Cuneo) applied to post-
treatment scans, we calculated the diagnostic accuracy for Tref, Nref, and composite
TNref. It was expressed in terms of sensitivity (SE), specificity (SP), PPV, NPV, and
overall accuracy. The semi-quantitative metabolic parameters were expressed as delta
value, defined as the difference of standardized uptake value corrected for body weight
(SUV/bw) and for lean body mass (SUL) values between the baseline and post-
treatment scans, for both Tref and Nref. Descriptive values are presented as mean
(⌖SD), median, range, and tertiles. Mann-Whitney test was used to evaluate the differ-
ence on selected mean delta values by specific outcomes (LRC, PFS, and OS). Categor-
ical variables were also calculated according to median and tertiles values, respectively.
The association between categorical delta values and the outcomes (LRC, PFS, and OS)
was evaluated by simple cross-tables and appropriate chi-square test. Logistic models
were also performed to confirm the possible association by odd ratios (OR) and 95% CI
calculation. Chi-square test and logistic models were also used to evaluate the associ-
ation between PERCIST (JH et al., 2016) and EORTC (Young et al., 1999) criteria and
the outcomes (LRC, PFS, and OS). Differences were considered statistically significant
at the level of p < 0.05. Statistical analyses were performed using the IBM SPSS Statis-
tics software (Statistical Package for Social Science, version 22).
The primary endpoint of the study was to evaluate the PPV of Cuneo score in asses-
sing LRC after treatment. The secondary endpoints were to evaluate the overall diag-
nostic accuracy of Cuneo, Deauville and Hopkins criteria in response assessment; the
rate of interobserver agreement of Cuneo score assessed with Krippendorff’s alpha; the
correlation of FDG-PET/CT semiquantitative body-weighted and lean-body mass pa-
rameters at baseline scans and their delta (percentage of change) with LRC, PFS, and
OS; and the correlation of response assessment according to EORTC and PERCIST
criteria with LRC, PFS, and OS. Considering a PPV of 71.1% with post-treatment FDG-
PET/CT based on the work of Marcus et al. (Marcus et al., 2014), applying the experi-
mental 6-point Cuneo score was hypothesized to yield a 20% increase. It was therefore
assumed the null hypothesis (H0) that the PPV is 71.1% versus the alternative hypoth-
esis (Ha) that the PPV is 85.3%. With a significance level α = 0.05 and a power of 0.90
when the PPV is 85.3%, the required sample size with this design was 81 patients.
Results
Patients’ characteristics and treatment outcome
Between Jan. 2010 and Dec. 2015, a total of 350 patients from 11 centers were included
in our study. In view of the fact that the requested acquisition time of all PET scans
should be 60 + 10min. after injection, our final cohort consisted of 119 subjects.
Patients’ characteristics are shown in Table 2. At diagnosis, the median age was 60
years (range 19-84), with most patients in good general conditions (ECOG PS of 0-1 in
96.6% of cases) and a baseline median age-adjusted CCI of 4. The most common pri-
mary site was oropharynx (57.1%): overall, most patients in our study had a locally ad-
vanced disease (91.5% with stage III-IV) and HPV negative status (73.1%). Primary
treatment was heterogeneous, with concurrent CRT as prevalent modality (54.6%). No
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patients underwent a planned neck dissection. The mean time intervals from baseline
PET execution to start of treatment and from its end to final PET execution were 3.1
and 16.6 weeks, respectively. At a median follow-up of 42 months (range 5-98), the me-
dian LRC, PFS, and OS were 35 (95% CI, 32-43), 33 (95% CI, 30-40), and 45.5 (95% CI,
39-51) months, respectively. The 3-year rates of LRC, PFS, and OS were 74.5%, 61.3%,
and 82.2%, respectively (Fig. 1 and supplementary figures 1-2). Overall, 28/119 patients
(23.5%) were censored for loco-regional recurrence.
FDG-PET/CT training phase
The application of Hopkins, Cuneo, and Deauville scores for post-treatment response
assessment yielded different score distributions, as shown in Fig. 2. Regarding the inter-
observer agreement, the Krippendorff’s alpha values for Tref and Nref evaluated at the
3-time points of assessment are reported in Table 3.
Accuracy of FDG-PET/CT-based qualitative scores
In light of the reported good interobserver agreement, we then assessed as primary
endpoint the diagnostic accuracy of the 3 qualitative reporting scales to rule out loco-
regional failure at post-treatment scan, primarily in terms of PPV (Table 4, supplemen-
tary table 1). The equivocal scores (3 and 4 according to Cuneo score and 3 according
to Deauville score) were clustered at time of analysis with definite positive and negative
findings in order to identify the best diagnostic threshold. Overall, Cuneo score no. 1
(with scores 3 and 4 clustered with 1 + 2, indicative of absence of disease) yielded the
best PPV for all categories (Tref, Nref, and TNref of 42.9%, 100%, and 50%, respect-
ively). In addition, it also had the highest TNref overall accuracy (76.5%), followed by
Cuneo score no. 2 (score 3 clustered with 1 + 2, score 4 clustered with 5 + 6, indicative
of persistent disease), Hopkins score, Deauville score no. 1 (score 3 clustered with 1 +
2, indicative of absence of disease), Cuneo score no. 3 (scores 3 and 4 clustered with 5
+ 6, indicative of residual disease), and Deauville score no. 2 (score 3 clustered with 4 +
5, indicative of residual disease) with 68.1%, 68.1%, 68.1%, 61.3%, and 54.6%, respect-
ively. Pictorial examples of Tref and Nref scoring with the 3 scales are shown in supple-
mentary figures 3 and 4, respectively.
Prognostic impact of FDG-PET/CT semi-quantitative parameters
In order to evaluate whether any change of semi-quantitative parameters over time
could be of prognostic impact, delta values for Tref and Nref between baseline and
post-treatment scans were correlated with LRC, PFS, and OS. For this purpose, 109 pa-
tients were analyzed, since 10 subjects were excluded due to the fact that the baseline
FDG-PET/CT was performed during or at the completion of induction CHT. Patients
with a SUVmax reduction for Nref in the second tertile had a lower risk of death com-
pared to first and third tertiles (p = 0.046; OR for death, 0.27; 95% CI, 0.09-0.85, p =
0.025). All other variables (either as continuous or categorical) were not significantly
associated with efficacy outcomes. When standardized semi-quantitative response as-
sessments were applied, no correlation could be found between EORTC criteria and
LRC, PFS, and OS, whereas nodal PD according to PERCIST criteria was associated
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Table 2 Patients’ disease and treatment characteristics
Characteristic No. of patients (%) n = 119








Charlson comorbidity index (age-adjusted)
< 4 53 (44.5)
4-7 61 (51.3)
≥ 8 5 (4.2)
Smoking history (pack/years)
0 19 (21.2)
< 10 15 (16.6)
10-20 11 (12.2)



























Induction CT + RT 2 (1.7)
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with a higher risk of loco-regional failure (p = 0.026; OR for LR failure, 5.65; 95% CI,
1.26-25.46, p = 0.024) and death (p = 0.04; OR for death, 4.81; 1.07-21.53, p = 0.04).
At Cox regression univariate analysis, the use of induction (p = 0.035) and concurrent
CHT (p = 0.0001) correlated with better OS, whereas a higher risk of death was found
for patients with baseline PS 2 (p = 0.001). In addition, a Cuneo score of 5-6 was also
indicative of poor prognosis (p = 0.0001), which retained statistical significance at
multivariate analysis (HR 6.0; 95% CI, 1.88-19.18; p = 0.002). No correlation was ob-
served in respect with CCI (< or ≥ 4), stage (IV vs others) and HPV status.
Discussion
Supported by high level of evidence (Mehanna et al., 2016), the use of FDG-PET/CT
after definitive CRT is recommended for HNSCC; however, the lack of a validated in-
terpretation system prevents from cross-comparisons among studies and accurate prog-
nostication in clinical practice. In the present multicenter study, we preliminarily
validated the use of Cuneo score, a 6-point qualitative scale by assessing its feasibility
and inter-reader agreement and by demonstrating an improvement in PPV after CRT
with respect to other score-based approaches previously proposed in this clinical set-
ting. The clinical relevance of applying standardized qualitative criteria in treatment re-
sponse assessment with FDG-PET/CT is epitomized by the widespread reproducibility
Table 2 Patients’ disease and treatment characteristics (Continued)
Characteristic No. of patients (%) n = 119
Induction CT + RCT 23 (19.3)
Induction CT + BRT 2 (1.7)
CRT 65 (54.6)
BRT 13 (10.9)
Fig. 1 Loco-regional control (Kaplan-Meyer method)
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and prognostic validity of Deauville score in HL (Kobe et al., 2018). In comparison to
it, only limited data are thus far available for solid malignancies (Helsen et al., 2018;
Scarsbrook et al., 2017; Huang et al., 2019). In this context, the Hopkins criteria repre-
sent the only proposed scoring system available for qualitative evaluation of post-
treatment FDG-PET/CT in HNSCC. This 5-point scale is essentially based on the
adoption of internal jugular vein (IJV) activity as blood-pool background reference. A
well conducted prospective study (Van Den Wyngaert et al., 2017) showed that the ap-
plication of Hopkins criteria allowed to obtain a lower rate of equivocal findings in
comparison with non-standardized local read (1.6% vs 10.4%, p = .003), whereas the
overall diagnostic accuracy was not improved (AUC of 0.78 and 0.73, respectively, p =
.336). The available data (Marcus et al., 2014; Van Den Wyngaert et al., 2017) suggest
that this scale may not be the best solution to address the inherently suboptimal PPV
of FDG-PET/CT assessment in HNSCC. In this perspective, the rationale behind the
design of the 6-tiered Cuneo score lied in replacing the activity of IJV as background
reference with those of mediastinal blood pool (MBP) and liver and in comparing the
FDG-avid spot with the local background. In case of residual uptake above the MBP,
Fig. 2 Score distribution of FDG-PET/CT post-treatment scans according to used standardized reporting
criteria (Deauville, Hopkins and Cuneo scores). Post-treatment scans classified as positive or negative for
residual tumor (black and grey bars, respectively) based on composite TNref score
Table 3 Krippendorff’s alpha values for inter-observer agreement throughout 3 rounds of revision
of post-treatment FDG-PET/CT scans for Tref (defined as the area with highest FDG uptake within
the residual primary tumor) and Nref (defined as the residual lymph node with highest FDG
uptake)
TRef NRef
Deauville score Hopkins score Cuneo score Deauville score Hopkins score Cuneo score
Phase 1 0.29 0.09 0.31 0.02 0.07 0.15
Phase 2 0.49 0.37 0.36 0.47 0.41 0.58
Phase 3 0.48 0.45 0.34 0.40 0.38 0.36
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Table 4 Overall diagnostic accuracy using standardized reporting criteria (Deauville, Hopkins, and
Cuneo scores)
Hopkins score (HS) Tref Nref TNref
1, 2, 3: absent disease
4, 5: persistent disease
Characteristic
Sensitivity 39.3 10.7 50.0
Specificity 75.8 96.7 73.6
NPV 80.2 77.9 82.7
PPV 33.3 50.0 36.8
Overall accuracy 67.2 76.5 68.1
Cuneo score (CS # 1) Tref Nref TNref
1, 2, 3, 4: absent disease
5, 6: persistent disease
Characteristic
Sensitivity 10.7 35.7 14.3
Specificity 95.6 100 95.6
NPV 77.7 77.1 78.4
PPV 42.9 100 50.0
Overall accuracy 75.6 77.5 76.5
Cuneo score (CS # 2) Tref Nref TNref
1, 2, 3: absent disease
4, 5, 6: persistent disease
Characteristic
Sensitivity 39.3 10.7 50
Specificity 75.8 96.7 73.6
NPV 80.2 77.9 82.7
PPV 33.3 50 36.8
Overall accuracy 67.2 76.5 68.1
Cuneo score (CS # 3) Tref Nref TNref
1, 2: absent disease
3, 4, 5, 6: persistent disease
Characteristic
Sensitivity 53.6 17.9 57.1
Specificity 64.8 94.5 62.6
NPV 81.9 78.9 82.6
PPV 31.9 50 32
Overall accuracy 62.2 76.5 61.3
Deauville score (DS # 1) Tref Nref TNref
1, 2, 3: absent disease
4, 5: persistent disease
Characteristic
Sensitivity 39.3 10.7 50.0
Specificity 75.8 96.7 73.6
NPV 80.2 77.9 82.7
PPV 33.3 50.0 36.8
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we envisaged to correlate the relationship between the focal uptake and local back-
ground with the liver activity, in order to take into account the known “contrast illusion
effect” which may be particularly relevant in head and neck anatomy. Overall, we
sought to design a scale with a more gradual shift in scoring based on the local back-
ground activity, aiming for a better clusterization of false positives compared with Hop-
kins criteria. Following a standardized concordance methodology widely adopted in HL
scenario (Biggi et al., 2013), a good inter-reader agreement was achieved in our work.
Despite its potentially high degree of complexity, the Cuneo score was prospectively
shown to be feasible with adequate reproducibility. In addition, no difference was ob-
served in terms of inter-reader agreement comparing Cuneo score with Hopkins and
Deauville criteria. While Hopkins criteria were already externally validated in a single-
center retrospective experience (Kendi et al., 2017) and ECLYPS study (Van Den
Wyngaert et al., 2017) with excellent concordance, the experimental application of
Deauville score to HNSCC response assessment is a peculiar finding of our work.
Clearly, prospective studies are required to further confirm the reliability of Cuneo
score for standardized reporting. As already mentioned, when the Cuneo score thresh-
old differentiating absence and residual disease was set between scores 4 and 5 (CS no.
1), the highest PPV rates were obtained. In particular, achieving 100% nodal PPV is of
extreme interest; in our opinion, this finding may lend support to the beneficial adop-
tion of a 6-point scale essentially centered on the local background activity to rule out
false-positive interpretations of irradiated lymph nodes, a critical issue for HNSCC.
From a clinical perspective, the ability to discriminate with excellent accuracy the pres-
ence of residual nodal disease may allow the early implementation of salvage surgery,
whereas the recognition of a false positive finding with high reliability may spare un-
necessary morbidity avoiding a neck dissection. In contrast, the suboptimal PPV rate
(42.9%) reported for primary tumor assessment underlines the importance of integrat-
ing two or more imaging modalities and clinical feedback for this specific purpose
(Jentsch et al., 2015). Regarding NPV, the results obtained with Hopkins, Deauville, and
Cuneo scores were similar, in the range of 80%, thus less than usually expected in this
context. Since we did not limit our post-treatment evaluation to a 6-month timepoint,
taking also into account that the mean time to loco-regional failure in our cohort was
of 16 months and that 53% (15/28) of loco-regional recurrences occurred after 1 year
Table 4 Overall diagnostic accuracy using standardized reporting criteria (Deauville, Hopkins, and
Cuneo scores) (Continued)
Overall accuracy 67.2 76.5 68.1
Deauville score (DS # 2) Tref Nref TNref
1, 2: absent disease
3, 4, 5: persistent disease
Characteristic
Sensitivity 64.3 17.9 67.9
Specificity 54.9 85.7 50.5
NPV 83.3 77.2 83.6
PPV 30.5 27.8 29.7
Overall accuracy 57.1 69.7 54.6
NPV negative predictive value, PPV positive predictive value
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from the end of RT, we think that the less than excellent NPV results reflect a time-
dependent loss of accuracy to detect late relapses, a finding also shown in the ECLYPS
study (Van Den Wyngaert et al., 2017). On top of excluding almost two-thirds of po-
tential candidate patients from our retrospective analysis, our attempt to follow a rigor-
ous centralized assessment implied that the 3 reviewers were blinded to all clinical data
and could not examine computed tomography or magnetic resonance of any individual
case, whenever performed. On the one hand aiming to increase the reviewers’ objectiv-
ity, on the other, we think that this was the main reason why all our qualitative inter-
pretations underperformed in terms of PPV, particularly for Tref response assessment,
falling short of what initially hypothesized. In other words, the strictly blinded review
we performed could have contributed to skew our results towards worse overall accur-
acy, compared with what may be achieved in clinical practice. Additional limitations
have to be acknowledged in the interpretation of our results. First, in spite of the out-
lined inclusion criteria, the retrospective nature of our study and the inherent clinical
heterogeneity cannot be overlooked. Second, the HPV positive subgroup was much less
represented that in the original paper by Marcus et al. (Marcus et al., 2014) (32 vs 123
patients, 26.9% vs 57.5% of the whole sample, respectively), thus restraining us from
drawing correlations between the diagnostic performance of Cuneo score and the false
positives related to the slow nodal clearance of HPV positive HNSCC. Third, the rela-
tively low number of our sample and of loco-regional recurrences may limit the
strength of our findings. Finally, no attempt was performed to correlate the post-
treatment qualitative scores with nodal morphologic features (Wray et al., 2016) or
radiation planning dosimetry (Morgan et al., 2019). When analyzing the semi-
quantitative FDG-PET/CT variables and their delta values between pre- and post-
treatment scans, no definitive conclusions can be drawn, except for the unfavorable
prognostic impact of nodal progression according to PERCIST criteria. Notably, the
significant correlation found between a Cuneo score indicative of persistent disease (5
and 6 according to Cuneo score no. 1) and poor OS reinforces the assumption that the
application of standardized qualitative criteria may be well suited for clinical prognosti-
cation. Although our data need to be interpreted with caution in light of the peculiar
methodology we followed, the results obtained by applying the Cuneo score after CRT
in HNSCC are promising and deserve to be further investigated.
In conclusion, a standardized qualitative interpretation of FDG-PET/CT-based post-
treatment assessment in HNSCC is still largely underrepresented in clinical practice. A
6-point scale such as the Cuneo score is feasible and may allow for better discrimin-
ation in respect to PPV, compared with the Hopkins criteria. To further elucidate its
reproducibility and overall diagnostic accuracy, prospective studies are warranted.
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